The absorption of pirarubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer

Yumiko Yamamoto, Yasutomo Nasu, T. Saika, T. Akaeda, T. Tsushima, H. Kumon

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objectives To assess the validity of the prophylactic use of pirarubicin ([2'R]-4-O-tetrahydropyranyl-doxorubicin) immediately after transurethral resection of bladder tumour (TURBT), using pharmacodynamic studies. Patients and methods The study included 20 consecutive patients with superficial bladder cancer. Pirarubicin (30 mg/50 mL or 30 mg/100 mL, 10 patients each) was instilled immediately after TURBT and retained in the bladder for 1 h. Blood samples were obtained before and at 15, 30, 60 and 120 min after the instillation. After retaining the drug for 1 h all the intravesical fluid was collected and assayed for pirarubicin. Results The plasma pirarubicin concentration in those receiving either dose was below detectable levels at any time after instillation. The mean recovery rate of pirarubicin in the drained fluid was 73%. Conclusion The intravesical instillation of pirarubicin immediately after TURBT caused no detectable plasma concentration and few systemic side-effects.

Original languageEnglish
Pages (from-to)802-804
Number of pages3
JournalBJU International
Volume86
Issue number7
DOIs
Publication statusPublished - 2000

Fingerprint

Urinary Bladder Neoplasms
Intravesical Administration
Doxorubicin
pirarubicin
Urinary Bladder
Pharmaceutical Preparations

Keywords

  • Absorption
  • Intravesical instillation
  • Pirarubicin
  • Superficial bladder cancer
  • Transurethral resection

ASJC Scopus subject areas

  • Urology

Cite this

The absorption of pirarubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer. / Yamamoto, Yumiko; Nasu, Yasutomo; Saika, T.; Akaeda, T.; Tsushima, T.; Kumon, H.

In: BJU International, Vol. 86, No. 7, 2000, p. 802-804.

Research output: Contribution to journalArticle

@article{b8a641be990f4bc1b4830718bef657bd,
title = "The absorption of pirarubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer",
abstract = "Objectives To assess the validity of the prophylactic use of pirarubicin ([2'R]-4-O-tetrahydropyranyl-doxorubicin) immediately after transurethral resection of bladder tumour (TURBT), using pharmacodynamic studies. Patients and methods The study included 20 consecutive patients with superficial bladder cancer. Pirarubicin (30 mg/50 mL or 30 mg/100 mL, 10 patients each) was instilled immediately after TURBT and retained in the bladder for 1 h. Blood samples were obtained before and at 15, 30, 60 and 120 min after the instillation. After retaining the drug for 1 h all the intravesical fluid was collected and assayed for pirarubicin. Results The plasma pirarubicin concentration in those receiving either dose was below detectable levels at any time after instillation. The mean recovery rate of pirarubicin in the drained fluid was 73{\%}. Conclusion The intravesical instillation of pirarubicin immediately after TURBT caused no detectable plasma concentration and few systemic side-effects.",
keywords = "Absorption, Intravesical instillation, Pirarubicin, Superficial bladder cancer, Transurethral resection",
author = "Yumiko Yamamoto and Yasutomo Nasu and T. Saika and T. Akaeda and T. Tsushima and H. Kumon",
year = "2000",
doi = "10.1046/j.1464-410X.2000.00911.x",
language = "English",
volume = "86",
pages = "802--804",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - The absorption of pirarubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer

AU - Yamamoto, Yumiko

AU - Nasu, Yasutomo

AU - Saika, T.

AU - Akaeda, T.

AU - Tsushima, T.

AU - Kumon, H.

PY - 2000

Y1 - 2000

N2 - Objectives To assess the validity of the prophylactic use of pirarubicin ([2'R]-4-O-tetrahydropyranyl-doxorubicin) immediately after transurethral resection of bladder tumour (TURBT), using pharmacodynamic studies. Patients and methods The study included 20 consecutive patients with superficial bladder cancer. Pirarubicin (30 mg/50 mL or 30 mg/100 mL, 10 patients each) was instilled immediately after TURBT and retained in the bladder for 1 h. Blood samples were obtained before and at 15, 30, 60 and 120 min after the instillation. After retaining the drug for 1 h all the intravesical fluid was collected and assayed for pirarubicin. Results The plasma pirarubicin concentration in those receiving either dose was below detectable levels at any time after instillation. The mean recovery rate of pirarubicin in the drained fluid was 73%. Conclusion The intravesical instillation of pirarubicin immediately after TURBT caused no detectable plasma concentration and few systemic side-effects.

AB - Objectives To assess the validity of the prophylactic use of pirarubicin ([2'R]-4-O-tetrahydropyranyl-doxorubicin) immediately after transurethral resection of bladder tumour (TURBT), using pharmacodynamic studies. Patients and methods The study included 20 consecutive patients with superficial bladder cancer. Pirarubicin (30 mg/50 mL or 30 mg/100 mL, 10 patients each) was instilled immediately after TURBT and retained in the bladder for 1 h. Blood samples were obtained before and at 15, 30, 60 and 120 min after the instillation. After retaining the drug for 1 h all the intravesical fluid was collected and assayed for pirarubicin. Results The plasma pirarubicin concentration in those receiving either dose was below detectable levels at any time after instillation. The mean recovery rate of pirarubicin in the drained fluid was 73%. Conclusion The intravesical instillation of pirarubicin immediately after TURBT caused no detectable plasma concentration and few systemic side-effects.

KW - Absorption

KW - Intravesical instillation

KW - Pirarubicin

KW - Superficial bladder cancer

KW - Transurethral resection

UR - http://www.scopus.com/inward/record.url?scp=0033762604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033762604&partnerID=8YFLogxK

U2 - 10.1046/j.1464-410X.2000.00911.x

DO - 10.1046/j.1464-410X.2000.00911.x

M3 - Article

VL - 86

SP - 802

EP - 804

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 7

ER -